Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, Clinical Pathways, begins this next segment from a different perspective.
Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, Clinical Pathways, begins this next segment from a different perspective.
He begins by discussing how a large aging population means that the incidence of cancer is rising. With that influx comes complexity and greater chronicity. To care for this requires innovation, but with that innovation comes cost.
He suggests that organizations like Cardinal Health provide one example of how organizations are successfully navigating clinical pathways. Several things set them apart from the competition, including interactive technology and “behavioral economics of medicine.” He says that reluctance in adopting effective models in clinical pathways is a “culture of medicine” issue: “I would argue that this is not necessarily a performance issue that’s related to value versus volume, it’s not a reimbursement problem, and I’m not convinced it’s an evidence problem. What I do believe, it’s a cultural problem, and our culture of medicine impacts our doctors and it impacts our patients, and if we don't get to the culture of medicine issue, then we’re really ignoring the elephant in the room. It’s a culture of medicine which embraces now over later, new over old, and more over less.”
In order to be an effective leader such as Cardinal Health, Dr Feinberg says that organizations should focus on behaviors with the greatest impact on cost and quality, engage physicians intensively, provide patient education in real time, and provide the health information technology solutions that allow providers to engage with patients in real time.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2
September 7th 2025Treatment of EGFR-mutated non–small cell lung cancer (NSCLC) is shifting toward next-generation sequencing and combination regimens that improve survival but increase toxicity, requiring individualized care.
Read More
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More